Pleural effusion is an accumulation of fluid in the pleural space, between the two layers of pleura. This fluid can be transudative or exudative. Transudative pleural effusion is the most common type of pleural effusion and is caused by an imbalance between hydrostatic and oncotic pressures in the pleural space. This imbalance leads to the accumulation of fluid in the pleural space. It is important for doctors to understand the causes, diagnosis, and treatment of transudative pleural effusion in order to properly treat patients with this condition.
Transudative pleural effusion is usually caused by an underlying systemic disorder. Common causes include congestive heart failure, cirrhosis, hypoalbuminemia, and nephrotic syndrome. Other causes include pulmonary embolism, hypothyroidism, and lupus. In some cases, the cause of transudative pleural effusion is unknown, and this is known as idiopathic transudative pleural effusion.
The diagnosis of transudative pleural effusion is based on the results of a physical examination, chest x-ray, and pleural fluid analysis. A physical examination can provide clues to the underlying cause of the effusion, such as the presence of edema or ascites. Chest x-ray can help to identify the presence and extent of pleural effusion. Pleural fluid analysis can help to distinguish between transudative and exudative effusions. The pleural fluid analysis includes measuring the pleural fluid protein, glucose, and lactate dehydrogenase levels. The pleural fluid protein level is typically lower than the serum protein level in transudative effusions. The pleural fluid glucose level is typically lower than the serum glucose level. The pleural fluid lactate dehydrogenase level is typically lower than the serum lactate dehydrogenase level.
The treatment of transudative pleural effusion depends on the underlying cause. If the cause is congestive heart failure, then treatment may include diuretics and other medications to reduce the fluid accumulation. If the cause is cirrhosis, then treatment may include medications to reduce the ascites. If the cause is hypoalbuminemia, then treatment may include intravenous albumin. In some cases, the cause of transudative pleural effusion is unknown and the effusion may resolve on its own. In these cases, the patient may be monitored with periodic chest x-rays to ensure that the effusion is not progressing.
Transudative pleural effusion is a common condition that is caused by an underlying systemic disorder. It is important for doctors to understand the causes, diagnosis, and treatment of transudative pleural effusion in order to properly treat patients with this condition. Treatment may include medications to reduce the fluid accumulation or to address the underlying cause. In some cases, the effusion may resolve on its own. With proper diagnosis and treatment, patients with transudative pleural effusion can be managed effectively.
1.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
2.
The main subject is associated with suicide in the United States.
3.
Alkem introduces cetuximab under the trade name Cetuxa in India.
4.
Firefighters who eat better can combat cancer.
5.
How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace
1.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
2.
Progressive Insights in Hematology in the Digital Era
3.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
4.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
5.
The Rise of Immunotherapy: New Advances in Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
2.
Blood Clotting Disorders Explained
3.
Sickle Cell Disease Explained
4.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation